Acupath Team, Author at Acupath Laboratories

Lumea, AIRA Matrix, and Acupath have Partnered to Provide a Diagnostic AI Solution for the URO17® Bladder Cancer Biomarker

March 21, 20250

LEHI, UT, UNITED STATES, March 20, 2025 /EINPresswire.com/ — Lumea, a leader in digital pathology solutions. AIRA Matrix Private Limited, an innovative technology company for AI-based diagnostic, prognostic, and predictive applications in cancer care. Acupath, a leading provider of sub-specialized anatomic and molecular pathology services. These companies have joined forces to deliver an AI-based solution to...

Cancer Awareness

What is Flow Cytometry?

February 18, 20240

Understanding the Importance of Flow Cytometry: Flow cytometry is a high sensitivity laboratory technique that plays a crucial role in diagnosing and staging leukemias and lymphomas, and for monitoring the treatment progress of cancer patients. Flow is also critical for monitoring infectious diseases (like HIV) and auto-immune disorders (like Lupus). Flow Cytometry Test Overview: Cells...

Health Management

The Vital Role of Regular Physicals in Maintaining Optimal Health

November 27, 20230

Acupath recognizes that good health is a precious asset that forms the cornerstone of a fulfilling and productive life. As 2023 is shortly coming to an end and 2024 is right around the corner, one often overlooked aspect of maintaining well-being is the importance of regular physical examinations. While many individuals may adopt healthy lifestyle...

Cancer Awareness

National Summer Sun Safety Month – August

August 8, 20230

UV RAYS FROM THE SUN CAUSES DNA DAMAGE, WHICH LEADS TO SKIN CANCER, EYE ISSUES AND PREMATURE AGING. The five-year survival rates for patients diagnosed with melanoma are: 99 percent when the cancer is localized 74 percent when the cancer has spread nearby 36 percent when the cancer has metastasizedNearly 20 Americans die from melanoma...

Press Release

Acupath Adopts Lumea Digital Pathology

May 19, 20230

LEHI, UT, May 16, 2023—Lumea, a leader in integrated digital pathology solutions, is pleased to announce that Acupath is partnering with Lumea to adopt the Lumea+ Viewer, leveraging its modular capability, well-rounded solutions, and flexibility. Lumea+ integrates Lumea’s leading-edge technology and proprietary consumables with any existing LIS. This upgraded system provides a seamless and easy transition...

Cancer Awareness

Bladder Cancer: How It Affects Men vs. Women

May 4, 20230

The common thought surrounding bladder cancer is that it is a disease that older men are diagnosed with. Fact is that men are more likely to be diagnosed earlier than women. When men present with blood in their urine (hematuria), it will be addressed and diagnosed quickly. Many women ignore hematuria in their urine because...

Respiratory Viruses

RSV: What is it and who is at risk?

March 22, 2023

Respiratory Syncytial Virus (RSV) is a contagious virus that has the potential to severely affect the lungs and respiratory airways. It can seem like a cold, but may be severe, especially in children and senior adults over age 65. But it can affect any one of any age. It can mimic the same symptoms as...

Cancer Awareness

COLORECTAL CANCER – WHO IS AT RISK?

March 7, 2023

At the start of the COVID-19 pandemic, colorectal cancer screenings dropped roughly 90% and diagnoses fell by 32%. Regular colorectal cancer screening is one of the most powerful tools against colorectal cancer. Screening can often find colorectal cancer early, when it’s small, hasn’t spread, and might be easier to treat. At Acupath, Molecular Biomarker testing helps...

Blog

Lumea, AIRA Matrix, and Acupath have Partnered to Provide a Diagnostic AI Solution for the URO17® Bladder Cancer Biomarker

What is Flow Cytometry?

The Vital Role of Regular Physicals in Maintaining Optimal Health

National Summer Sun Safety Month – August

Acupath Adopts Lumea Digital Pathology

Bladder Cancer: How It Affects Men vs. Women

RSV: What is it and who is at risk?

COLORECTAL CANCER – WHO IS AT RISK?

March 21, 2025Lumea, AIRA Matrix, and Acupath have Partnered to Provide a Diagnostic AI Solution for the URO17® Bladder Cancer Biomarker

February 25, 2025The Flu is Surging Across the U.S.

July 18, 2024How common is Bone Cancer?

May 13, 2024Differences Between Urinalysis Urine Cytology AcuURO17

March 29, 2024Three digital pathology leaders converge to streamline processes, enhance diagnostics, and improve patient outcomes